Phase 2/3 COVID-19 Candidate Opaganib reduces acute respiratory distress syndrome-related blood clotting in preclinical animal model

Researchers state this latest finding points towards another important potential benefit of opaganib to COVID-19 patients – in addition to the already established inhibition of SARS-CoV-2 replication and the potential reduction in hyper immune-response by opaganib.

Source:

Biospace Inc.